Selected research
Industry Research
N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Research Report 2026
Market perspective
The global N-Acetylglutamate Synthetase Deficiency (NAGSD) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the N-Acetylglutamate Synthetase Deficiency (NAGSD) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the N-Acetylglutamate Synthetase Deficiency (NAGSD) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the N-Acetylglutamate Synthetase Deficiency (NAGSD) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of N-Acetylglutamate Synthetase Deficiency (NAGSD) include Grand Pharmaceutical Group, Lee's Pharmaceuticals, Sovereign Medical, Sigmapharm Laboratories, Recordati Rare Diseases, Medunik, Immedica, Amgen and Acer Therapeutics. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to N-Acetylglutamate Synthetase Deficiency (NAGSD).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
N-Acetylglutamate Synthetase Deficiency (NAGSD) Market by Company
Grand Pharmaceutical Group
Lee's Pharmaceuticals
Sovereign Medical
Sigmapharm Laboratories
Recordati Rare Diseases
Medunik
Immedica
Amgen
Acer Therapeutics
N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Type
Original Drug
Generic Drug
N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Application
Adults
Children
N-Acetylglutamate Synthetase Deficiency (NAGSD) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of N-Acetylglutamate Synthetase Deficiency (NAGSD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of N-Acetylglutamate Synthetase Deficiency (NAGSD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of N-Acetylglutamate Synthetase Deficiency (NAGSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Drug
- Generic Drug
Applications
- Adults
- Children
Companies covered
- Grand Pharmaceutical Group
- Lee's Pharmaceuticals
- Sovereign Medical
- Sigmapharm Laboratories
- Recordati Rare Diseases
- Medunik
- Immedica
- Amgen
- Acer Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Original Drug
- 2.2.3 Generic Drug
- 2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Adults
- 2.3.3 Children
- 2.4 Assumptions and Limitations
3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Breakdown Data by Type
- 3.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Type (2021-2026)
- 3.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Type (2027-2032)
4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Breakdown Data by Application
- 4.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Application (2021-2026)
- 4.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Perspective (2021-2032)
- 5.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Growth Trends by Region
- 5.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Region (2021-2026)
- 5.2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Region (2027-2032)
- 5.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Dynamics
- 5.3.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends
- 5.3.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Drivers
- 5.3.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Challenges
- 5.3.4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players by Revenue
- 6.1.1 Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players by Revenue (2021-2026)
- 6.1.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Players (2021-2026)
- 6.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD) Head Office and Area Served
- 6.4 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Players, Product Type & Application
- 6.5 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Manufacturers Established Date
- 6.6 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
- 7.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021-2026)
- 7.4 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
- 8.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021-2026)
- 8.4 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
- 9.2 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
- 10.2 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021-2026)
- 10.4 South America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021-2032)
- 11.2 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Grand Pharmaceutical Group
- 12.1.1 Grand Pharmaceutical Group Company Information
- 12.1.2 Grand Pharmaceutical Group Business Overview
- 12.1.3 Grand Pharmaceutical Group Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.1.4 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.1.5 Grand Pharmaceutical Group Recent Developments
- 12.2 Lee's Pharmaceuticals
- 12.2.1 Lee's Pharmaceuticals Company Information
- 12.2.2 Lee's Pharmaceuticals Business Overview
- 12.2.3 Lee's Pharmaceuticals Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.2.4 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.2.5 Lee's Pharmaceuticals Recent Developments
- 12.3 Sovereign Medical
- 12.3.1 Sovereign Medical Company Information
- 12.3.2 Sovereign Medical Business Overview
- 12.3.3 Sovereign Medical Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.3.4 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.3.5 Sovereign Medical Recent Developments
- 12.4 Sigmapharm Laboratories
- 12.4.1 Sigmapharm Laboratories Company Information
- 12.4.2 Sigmapharm Laboratories Business Overview
- 12.4.3 Sigmapharm Laboratories Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.4.4 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.4.5 Sigmapharm Laboratories Recent Developments
- 12.5 Recordati Rare Diseases
- 12.5.1 Recordati Rare Diseases Company Information
- 12.5.2 Recordati Rare Diseases Business Overview
- 12.5.3 Recordati Rare Diseases Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.5.4 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.5.5 Recordati Rare Diseases Recent Developments
- 12.6 Medunik
- 12.6.1 Medunik Company Information
- 12.6.2 Medunik Business Overview
- 12.6.3 Medunik Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.6.4 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.6.5 Medunik Recent Developments
- 12.7 Immedica
- 12.7.1 Immedica Company Information
- 12.7.2 Immedica Business Overview
- 12.7.3 Immedica Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.7.4 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.7.5 Immedica Recent Developments
- 12.8 Amgen
- 12.8.1 Amgen Company Information
- 12.8.2 Amgen Business Overview
- 12.8.3 Amgen Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.8.4 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.8.5 Amgen Recent Developments
- 12.9 Acer Therapeutics
- 12.9.1 Acer Therapeutics Company Information
- 12.9.2 Acer Therapeutics Business Overview
- 12.9.3 Acer Therapeutics Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021-2026)
- 12.9.4 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product Portfolio
- 12.9.5 Acer Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst